Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Partnering

Viracta collaborates with leading scientific and clinical researchers, philanthropic and patient advocacy groups, and corporate partners to advance application of the Kick & Kill Platform for a range of cancers and serious diseases.

Partnerships

Shenzhen Salubris Pharmaceuticals Co. Ltd.

Partnership to develop and commercialize Viracta’s treatment approach to virus-associated malignancies in China. Read More

Visit Salubris

NantKwest, Inc.

Immunotherapy collaboration to evaluate nanatinostat in combination with natural killer (NK) cell therapies. Read More

Biocom

Partnership Opportunities

Nanatinostat (aka VRx-3996; formerly known as tractinostat or CHR-3996) has shown promise in animal models of human cancers to enhance a range of immunotherapy modalities, including checkpoint inhibitors and adoptive cell therapies such as CAR-T cell therapy, T cell receptor (TCR) as well as NK cell immunotherapy. This opens a range of potential product and partnering opportunities to evaluate both viral- and non-viral cancers, latent viral infections such as HIV/AIDS, and more.

While EBV cancers represent Orphan Drug opportunities in the US and Europe, many are prevalent in parts of Africa and Asia. Viracta is committed to helping patients around the world, and will partner in those geographies.

Contact: busdev@viracta.com

Partnering

Viracta collaborates with leading scientific and clinical researchers, philanthropic and patient advocacy groups, and corporate partners to advance application of the Kick & Kill Platform for a range of cancers and serious diseases.

Partnerships

Shenzhen Salubris Pharmaceuticals Co. Ltd.

Partnership to develop and commercialize Viracta’s treatment approach to virus-associated malignancies in China. Read More

Visit Salubris

NantKwest, Inc.

Immunotherapy collaboration to evaluate nanatinostat in combination with natural killer (NK) cell therapies. Read More

Biocom

Partnership Opportunities

Nanatinostat (aka VRx-3996; formerly known as tractinostat or CHR-3996) has shown promise in animal models of human cancers to enhance a range of immunotherapy modalities, including checkpoint inhibitors and adoptive cell therapies such as CAR-T cell therapy, T cell receptor (TCR) as well as NK cell immunotherapy. This opens a range of potential product and partnering opportunities to evaluate both viral- and non-viral cancers, latent viral infections such as HIV/AIDS, and more.

While EBV cancers represent Orphan Drug opportunities in the US and Europe, many are prevalent in parts of Africa and Asia. Viracta is committed to helping patients around the world, and will partner in those geographies.

Contact: busdev@viracta.com